A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Isolation of Chondrocytes and Chondroprogenitors Using Fibronectin Adhesion and Migratory Assay

1.7K views

⸱

DOI:

10.3791/67160

⸱

October 4th, 2024

 ,  ,  ,  , 
1Department of Physiology, Christian Medical College, 2Centre for Stem Cell Research (A unit of InStem, Bengaluru), Christian Medical College, 3Department of Orthopedics, Christian Medical College, 4Faculty of Health and Medical Sciences, The University of Adelaide, 5Department of Orthopedics and Trauma, Royal Adelaide Hospital

In This Article

Summary

This protocol details the isolation of chondrocytes, Fibronectin Adhesion Assay-derived Chondroprogenitors (FAA-CPs), and Migratory Chondroprogenitors (MCPs) from human articular cartilage. It covers enzymatic digestion, fibronectin adhesion, and migration-based assays for isolating and characterizing these cells.

Abstract

Chondroprogenitor cells (CPCs), recently identified as a distinct subpopulation, exhibit promise due to their mesenchymal properties, heightened chondrogenesis, and limited hypertrophic traits. The enrichment of progenitors is achieved through differential fibronectin adhesion and migration-based explant assays, with Fibronectin Adhesion Assay-derived Chondroprogenitors (FAA-CPs) and Migratory Chondroprogenitors (MCPs) demonstrating superior potential compared to chondrocytes. This article delves into the details of isolating resident cartilage-derived cells, namely chondrocytes and chondroprogenitors. While valuable insights from chondrocyte research contribute to our understanding of cartilage repair, ongoing efforts are directed toward the use of chondroprogenitors and exploring their potential as an alternative therapeutic approach. Additionally, this methodology article provides a detailed step-by-step protocol for isolating three specific cell types from cartilage: chondrocytes, FAA-CPs, and MCPs. By following standardized procedures, this protocol facilitates the successful extraction of these cell subtypes. Grounded in extensive research, the article focuses on the intricate techniques utilized in isolating the different subsets and the optimized culture conditions required to expand and maintain their cultures. The methodology encompasses enzymatic isolation of human articular cartilage-derived chondrocytes, differential fibronectin adhesion following sequential enzymatic digestion, and migration-based explant assays to obtain cartilage-resident cells.

Introduction

The emergence of cell-based regenerative therapy represents a significant approach to treating cartilage-related ailments, such as osteoarthritis (OA) and chondral defects1. These disorders, characterized by the breakdown or injury of cartilage within the joints, present substantial challenges during treatment. The self-repair of articular cartilage is reported to be limited due to its aneural architecture, avascularity, and low mitotic activity2.

The most utilized cells for cartilage tissue regeneration are Mesenchymal Stem Cells (MSCs) and chondrocytes3. However, several studies have reported limitations in using these cells for regeneration4. These limitations include the terminal differentiation of chondrocytes during extended in vitro expansion to achieve the required cell count and the hypertrophic tendency of MSCs. These factors can result in the formation of repair tissue with a suboptimal combination of fibrocartilage and hyaline5,6,7,8.

The discovery of Chondroprogenitor cells (CPCs) arose from the quest for alternative cells in articular cartilage9. They have generated immense interest due to their resemblance to MSCs and their superior chondrogenic potential, all while exhibiting reduced hypertrophy - an indispensable combination sought after10,11. In contrast to chondrocytes, these progenitor populations have been reported to exhibit enhanced replicative and telomerase activity, as well as increased expression of Neurogenic locus notch homolog protein 1 (NOTCH-1) and SRY-box transcription factor 9 (SOX-9)12,13,14,15. There are two standard methods to isolate CPCs reported both from cartilage and meniscus, including one based on their integrin receptor (CD49e/CD29) expression, isolated through a fibronectin adhesion assay - Fibronectin Adhesion Assay-derived Chondroprogenitors (FAA-CPs), and the other based on their heightened migratory potential from cartilage explants- Migratory Chondroprogenitors (MCPs)11,13,16,17,18,19. Numerous in vitro studies demonstrate the chondrogenic superiority and reduced hypertrophy of both FAA-CPCs and MCPs compared to chondrocytes and bone marrow (BM)-MSCs20,21,22,23.

Recent in vitro investigations comparing FAA-CPCs to MCPs have demonstrated the enhanced cartilage regeneration capacity of the latter progenitor population under normal oxygen conditions24. These optimistic in vitro results showcase a hyaline-like regeneration, encouraging further in vivo experiments. Nevertheless, both populations of CPCs have been reported to efficiently repair and regenerate cartilage in OA and other osteochondral disorders in animal models25,26,27,28,29.

Our laboratory has actively contributed to standardizing CPC isolation techniques and comparing their phenotypic characteristics with chondrocytes and MSCs. This article will provide a detailed protocol explaining the steps involved in isolating and culturing cartilage resident cells, namely chondrocytes, FAA-CPCs, and MCPs.

Access restricted. Please log in or start a trial to view this content.

Protocol

The protocol has been approved and complies with the appropriate regulations and guidelines of the Institutional Review Board (Research and Ethics Committee). After obtaining written informed consent, human tibiofemoral joints are procured from osteoarthritis (OA) patients (Kellgren-Lawrence radiological score 4)30 who require total knee replacement as part of their treatment. The joints of patients with any signs of tumors, infections, or inflammatory arthritis (such as rheumatoid arthritis or gout) were excluded from the study. It is ensured that all procedures are conducted under sterile conditions, adhering to standard laboratory protocols throughout the experimental process.

1. Obtaining tibiofemoral joints

  1. Obtain knee joints (tibiofemoral joints) from human donors requiring above-knee amputation as part of treatment or from those with Grade IV osteoarthritis30 (radiological evidence showing marked reduction of joint space with chondral sclerosis) undergoing total knee replacement.
    NOTE: Ensure that informed consent is obtained from patients following the Helsinki Declaration's principles. Ensure adherence to Ethics Committee and Institutional Review Board rules.
  2. Exclude any joints showing symptoms of infection or inflammation.

2. Processing harvested joints

  1. Place the harvested tibiofemoral joints in 1x phosphate-buffered saline (PBS) solution under sterile conditions.
  2. Prepare a sterile area under the hood by placing a sterile underpad. Transfer the harvested joints onto the underpad.
  3. Stabilize the sectioned tibiofemoral joints by holding the subchondral bone with the cartilage facing in the upward direction.
  4. Using a scalpel blade (no. 22), harvest rectangular-shaped cartilage shavings from the non-weight bearing areas for OA patients within 1-2 h of obtaining the joint.
  5. Harvest the cartilage sections of 8 mm x 10 mm from the superficial layer to the deeper layer.
  6. Wash the cartilage slices with 1x PBS solution and place them in a Petri dish containing 1-2 mL of plain DMEM medium.
  7. Mince the cartilage slices nicely to a size of less than 1 mm x 1mm x 1mm with a scalpel blade (no.22).
    NOTE: Ensure that the cartilage slices or minced cartilage do not dry out; place them in a culture medium or PBS devoid of serum.

3. Isolation of chondrocytes

  1. Place the minced cartilage in an upright T-25 flask containing 10 mL of Dulbecco's Modified Eagle Medium F12 (DMEM-F12) with 0.15% collagenase type II for enzymatic digestion. Leave the flask undisturbed for 12-14 h in a CO2 incubator, ensuring standard culture conditions31.
    NOTE: Plain DMEM-F12 medium without traces of serum should be used, as serum inactivates the enzymatic action.
  2. Following overnight digestion, transfer the medium containing the released cells into a fresh, sterile centrifuge tube containing an equal volume of DMEM-F12 + 10% Fetal Bovine Serum (FBS), using a cell strainer to separate the cells from the debris. The released cells are the "chondrocytes".
  3. Centrifuge the filtered cells at a speed of 1200 x g for 5 mins at 37 °C.
  4. Discard the supernatant without disturbing the pellet. Reconstitute the obtained pellet in 1 mL of medium and count the viable cells released using a trypan blue exclusion assay.
  5. Load the chondrocytes in a T-25 flask at a concentration of 10,000 cells/cm² and expand to the required passage number using DMEM-F12 containing 10% FBS. Additional components in the medium include ascorbic acid (62 µg/mL), L-glutamine (2.5 mM/L), penicillin-streptomycin (100 IU/mL), and amphotericin-B (2 µg/mL).
  6. Refresh the medium every 3 days and harvest cells at sub-confluence using 0.125% Trypsin containing Ethylenediamine tetraacetic acid (EDTA).

4. Isolation of Fibronectin Adhesion Assay-Derived Chondroprogenitors (FAA-CPs)

  1. 12 h prior to the release of the chondrocytes, prepare 10 mL of 1x PBS containing 1 mM of MgCl2 (10 µL) and 1 mM of CaCl2 (10 µL), and 100 µL of Fibronectin (10 µL/mL)32.
  2. Coat the required number of wells of a 6-well plate (1.5 mL/9.3 cm2) using the prepared solution.
  3. Seal the plate tightly and refrigerate overnight at 4 °C.
  4. Additionally, obtain cartilage shavings in a manner similar to that explained for isolation of chondrocytes (steps 2.1-2.5).
  5. Subject the cartilage shavings to sequential overnight enzymatic digestion (0.2% Pronase for 3 h; followed by 0.04% Collagenase type II for 12 h) in a shaking water bath maintained at 37 °C for obtaining individual chondrocytes.
  6. The following day, remove the Fibronectin-coated 6-well plate from the refrigerator and remove excess Fibronectin.
    NOTE: Excess Fibronectin should be removed slowly and gently without disturbing the coating on the bottom of the well. The presence of MgCl2 (10 µL) and 1 mM of CaCl2 is crucial to ensure the attachment of cells.
  7. Add 2-3 mL of plain DMEM-F12 medium into the coated wells.
  8. Seed the released chondrocytes onto the coated wells at a loading density of 4000 cells/well and leave the plate undisturbed for a period of 20 min.
  9. Post incubation, remove the excess media and non-adherent cells. Add 2-3 mL of standard growth media as used for chondrocytes (DMEM-F12 + 10% FBS).
  10. Maintain the adherent cells under standard culture conditions for 10-12 days to obtain CPC clones (colonies of >32 cells).
  11. Isolate using 0.125% trypsin-EDTA for 180 s, re-plate the clones at a ratio of 1 clone/5 cm², and expand the enriched polyclonal CPs to the required confluence. These cells obtained are referred to as the "FAA-CPCs".
  12. Culture the cells further in DMEM-F12 medium + 10% FBS + transforming growth factor beta 2 (TGFβ2: 1 ng/mL) + fibroblast growth factor (FGF2: 5 ng/mL).
    NOTE: The incubation of cells on fibronectin-coated plates should not exceed 20 min, as chondrocytes may also begin to adhere. During the 20 min adhesion period, the medium must be devoid of serum. Next, the cells that adhere to form clones must be cultured in a medium additionally containing FBS. The clones must be isolated only after ensuring that each clone has more than 32 cells; this is to avoid transit amplifiers. Further expansion of the clones after trypsinization should include the additional growth factors mentioned. A loading density of 4000 chondrocytes/9.3 cm2 of a fibronectin-coated plate, following a 20 min incubation followed by a wash, results in the adhesion of 80-100 cells in total. Out of these, around 20 clones will progress to grow and achieve a population doubling of 5 within 10-12 days.

5. Isolation of migratory chondroprogenitors

  1. Shave cartilage explants (10 mm x 5 mm x 1 mm ) from the harvested articular joint and place them in a sterile 6-well plate containing DMEM-F12 media with 10% FBS and 10 mM Glutamax (2-3 explants/well)33.
  2. Leave the plate with the explants undisturbed for 48 h in a CO2 incubator maintained at 37 °C.
  3. After 2 days, transfer the explants to a centrifuge tube containing 10 mL of 0.1% collagenase solution for enzymatic digestion. Incubate the tube at 37 °C for 2 h.
    NOTE: The explants require to be rinsed with 1x PBS before enzymatic digestion, as traces of serum can inactivate the enzyme action. For washing, dip the explants in a Petri dish filled with 2-3 mL of 1x PBS; this is also to ensure non-contamination with any released chondrocytes. The handling of the explants must be kept to a minimum, and this is to avoid stressing the progenitors that have started to migrate.
  4. Post digestion, rinse the explants with 1x PBS and place them back in the same wells of the plate containing fresh DMEM-F12 media with 10% FBS and 10 mM of Glutamax medium.
  5. Maintain the plate in standard culture conditions in the incubator. Observe for the migration of chondroprogenitors in the subsequent days.
  6. On reaching sub confluence, harvest the MCPs using 0.125% of Trypsin containing EDTA.
  7. Expand the MCPs using the standard expansion medium, which includes DMEM-F12, which contains 10% FBS and 10 mM of Glutamax.

6. Phenotypic characterization of chondrocytes, FAA-CPs and MCPs

  1. Flow Cytometric Analysis (FACS)
    NOTE: The following steps are followed for FACS analysis of the harvested cell groups.
    1. Trypsinize the cells as per standard protocol using 0.125% Trypsin and centrifuge at 1200 x g, 5 min, room temperature to obtain the cell pellet.
    2. Discard the supernatant, wash, and re-suspend the pellet with 1x PBS.
    3. Transfer the suspension to labeled tubes for FACS.
    4. Divide the suspension equally into two tubes: an 'unstained' tube that acts as a control (cell suspension without antibody) and 'stained' tubes that act as tests (cell suspension with antibody).
    5. Follow the technical data sheet of individual antibodies/Cluster of differentiation (CD) markers for staining. Antibodies for comparison include CD105-FITC, CD73-PE, CD90-PE, CD106-APC (positive expression markers); CD34-PE, CD45-FITC, and CD14-FITC (negative expression markers)34,35; CD166-BB515 and CD146-PE (potential chondrogenic markers)36,37.
      NOTE: CD markers are light-sensitive. To ensure the steps are done in the dark.
    6. Incubate the cell suspension with antibody for 30 min in the dark.
    7. Post staining, add 1 mL of 1x PBS to the tubes and centrifuge at 1200 x g, 5 min, room temperature to obtain the cell pellet.
    8. Discard three-fourths of the supernatant. Re-suspend the pellet in the remaining supernatant content by gentle trituration.
    9. Proceed for FACS analysis.

7. qRT-PCR

NOTE: qRT-PCR analysis of gene expression involves evaluation of Collagen type I (COL1A1), Collagen type X (COL10A1), and Runt-related transcription factor (RUNX2) for hypertrophic expression, and SOX-9, Aggrecan (ACAN), and Collagen type II (COL2A1) for chondrogenesis.

  1. Extract RNA from the cell groups using commercially available kits as per the manufacturer's instructions.
  2. Post extraction, evaluate the A260/A280 ratio and the RNA concentration.
  3. Utilize 280 ng of the extracted RNA to construct complementary DNA (cDNA).
  4. Initiate qRT-PCR using Sybr Green, each reaction containing a final concentration of 7 ng of cDNA on a thermocycler.
  5. Normalize each gene's relative mRNA expression to the GAPDH reference housekeeping gene (ΔCt).
  6. Calculate the relative expression of each gene using the 2-ΔΔCt technique by comparing each individual gene's ΔCt value to that of the FAA-CPs (ΔΔCt)37.

8. Multilineage differentiation

NOTE: Commercially available differential media induces trilineage differentiation into adipogenic, osteogenic, and chondrogenic lineages.

  1. For adipogenic differentiation, seed cells at a loading density of 1000 cells/cm2 in a cell culture plate and culture using adipogenic differentiation medium (medium change - once in 3 days) till a sub confluence of 80% for 3 weeks.
  2. For osteogenic and chondrogenic differentiation, follow the 28-day pellet culture system38.
  3. Centrifuge 0.5 x 106 cells at 400 x g for 12 min at 37 °C to form pellets and initiate differentiation using osteogenic and chondrogenic differentiation medium.
  4. Fix, embed, and section the pellets for confirmatory staining (step 9).

9. Confirmatory staining

  1. In the case of adipogenic lineage cells, fix the cells with buffered formalin, wash, and stain with Oil Red O (0.5%). Stain the controls (cultured on a standard DMEM medium with 10% FBS) as well.
  2. Observe under a microscope and acquire the images.
  3. For the differentiated osteogenic lineage cells, stain with Alizarin Red (2%).
    NOTE: Multiple confirmatory staining protocols are applicable for the chondrogenic differentiated cells.
  4. Alcian Blue staining: Stain the fixed cells with Alcian blue for 5 min and counterstain with Neutral Red.
  5. For assessing Glycosaminoglycan (GAG) content, perform Safranin O staining: Stain the slides with Wiegert's Iron Hematoxylin followed by subsequent incubation with acid alcohol (1%), fast green solution (0.05%), acetic acid (1%), and Safranin O solution (1%).
  6. Toluidine Blue staining: Stain the slides with Toluidine Blue (0.1%) for 5 min.
  7. PicroSirius Red staining: Stain the slides with Picrosirius Red (0.1%) and counterstain using Hematoxylin dye.
    NOTE: Following staining, dehydrate the slides using graded alcohol and clear using xylene. Mount slides using Dibutylphthalate Polystyrene Xylene (DPX) mountant, observe them under a microscope, and acquire images.
  8. For immunohistochemistry (type II collagen) staining of the chondrogenic differentiated pellet, subject the pellet sections to enzymatic antigen retrieval using the enzymes pronase (1 mg/mL) and hyaluronidase (2.5 mg/mL).
  9. Incubate the sections with primary mouse monoclonal anti-collagen type II antibody, followed by 1:250 secondary HRP labeled goat anti-mouse antibody.
  10. Stain the slides with 3,3′-Diaminobenzidine (DAB) chromogen and counterstain them using Hematoxylin.
  11. Observe under a microscope and capture images.

10. Determining GAG/DNA content

  1. Digest the chondrogenic differentiated pellets using papain-cysteine solution at 65 °C for 16 h.
  2. Estimate DNA concentration using Picrogreen reagent38 and acquire the fluorescence intensity at wavelengths- excitation: 480 nm, emission: 520 nm using an ELISA plate reader.
  3. Evaluate total GAG content using the dimethyl methylene blue dye method38.
  4. Measure optical density at 525 nm using an ELISA plate reader.
  5. Normalize the GAG values to the DNA values and calculate the total GAG/DNA ratio.

Access restricted. Please log in or start a trial to view this content.

Results

From 86.9 mg of cartilage slices, a chondrocyte cell yield of 1.72 x 105 cells was noted. Upon loading, chondrocytes promptly adhere, presenting an initial rounded cobblestone appearance and transforming into a fibroblastic state upon further expansion (Figure 1 A,B). Seeding these chondrocytes onto fibronectin plates typically results in 2% adhesion, with each cell undergoing clonal growth (Figure 2 C,D), reaching a ...

Access restricted. Please log in or start a trial to view this content.

Discussion

The potential regeneration of articular cartilage, containing hyaline tissue, may be achieved through the optimization of its two native cell types: chondrocytes and chondroprogenitors. While extensive research on chondrocytes has provided valuable insights into their role in cartilage repair, questions about the nature of the regenerated tissue have prompted efforts to enhance their phenotype and explore alternative therapies3. Chondroprogenitors, identified as a relatively recent cellular subpop...

Access restricted. Please log in or start a trial to view this content.

Acknowledgements

We would like to acknowledge Ms. Bhavini Krishnan and Ms.Merin Mary Zachariah for their intellectual input and the Centre for Stem Cell Research (A unit of inStem Bengaluru), Department of Physiology, Christian Medical College, Vellore, for infrastructural support. The ongoing projects are supported by the Department of Biotechnology (BT/PR32777/MED/31/415/2019), Govt. of India, Science and Engineering Research Board (CRG/2022/004277), Govt. of India, and Fluid Research Grants, Christian Medical College, Vellore.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
22-scalpel blade GLASS VAN
6-well plate CORNING3516
Alcian BlueTHERMO SCIENTIFICJ6012
Alizarin Red SIGMA130223
Amphotericin-B (2 μg/mL).GIBCO15240062
Ascorbic acid (62 μg/mL)SIGMA ALDRICHA4544-25G
BC CytoFLEX LX flow cytometer BECKMAN COULTERCYTExpert Software Version 2.5
CaCl2SIGMA ALDRICH C34006
CD105-FITCBD BIOSCIENCE561443
CD106-APCBD BIOSCIENCE551147
CD14-FITCBD BIOSCIENCE555397
CD29-APCBD BIOSCIENCE559883
CD34-PEBD BIOSCIENCE348057
CD45-FITCBD BIOSCIENCE347463
CD49b-FITCMILTENYL BIOTEC MACS 130/100337
CD49e-PEBD BIOSCIENCE555617
CD73-PEBD BIOSCIENCE550257
CD90-PEBD BIOSCIENCE561970
Cell counterDE NOVIXCell Drop BF
Cell strainerHIMEDIATCP024
CentrifugeBECKMAN COULTERAllegra X-30R
CO2 incubator THERMO SCIENTIFICMODEL-371
Collagen type X (COL10A1),Runt-related transcription factor (RUNX2),SRY-Box Transcription Factor 9 (SOX-9), Aggrecan (ACAN), and Collagen type II (COL2A1) EUROGENTEC, BELGIUM
Collagenase type IIWORTHINGTONLS004176
DMEM F-12 (Dulbecco's Modified Eagle's Medium F-12)SIGMA ALDRICHD8900-1L
ELISA plate readerMOLECULAR DEVICESSpectraMax i3x Reader
Fast GreenFISHER SIENTIFIC2353459
Fetal Bovine SerumGIBCO10270106
FGF2CLOUD CLONE CORPAPA551Hu01
Fibronectin (10 µL/mL)SIGMA ALDRICHF1141
First-Strand synthesis systemTAKARA BIO6110A
GlutamaxGIBCO35050061
HematoxylinQUALIGENSQ39411
MgCl2 SIGMA ALDRICHM8787
Oil Red OSIGMA1320065
PBS (Phosphate Buffered Saline)GIBCO10010023
PCR thermocycler APPLIED BIOSYSTEMSQuantstudio 12K Flex thermocycler 
Penicillin-streptomycin (100 IU/mL)GIBCO15240062
Picrosirius RedALFA AESAR2610108
Primary antibody (mouse Collagen type II)DSHBDSHB II II6B3
PronaseROCHE10165913103
Quant-iT Picogreen dsDNA reagentTHERMO SCIENTIFICP7589
RefrigeratorELANPRO
RNeasy MiniKitQIAGEN74104
Safranin OQUALIGENSQ39962
Secondary antibody (Goat Anti-Mouse IgG Antibody, HRP conjugate)THERMO SCIENTIFIC31430
Shaking water bath REMI
StemPro differentiating kits GIBCO1007201, A1007001, and A1007101
T-25 flask CORNING430639
TakyonTM Low Rox SYBR Master Mix dTTP Blue EUROGENTECUF-LSMT-B0701
TGFβABCAMab277760
Tissue Culture PetridishTARSONS960010
Toluidine BlueQUALIGENS2040
Tryphan blue GIBCO15250061
Trypsin EDTAGIBCO25200072

References

  1. Muthu, S., Visawanathan, V., Chellamuthu, G., Thabrez, M. Clinical effectiveness of various treatments for cartilage defects compared to microfracture: A network meta-analysis of randomized controlled trials. J Cartilage Joint Preserv. 4 (2), 100163(2023).
  2. Sophia Fox, A. J., Bedi, A., Rodeo, S. The basic science of articular cartilage. Sports Health. 1 (6), 461-468 (2009).
  3. Brittberg, M. Clinical articular cartilage repair-An up-to-date review. Annals of Joint. 3 (0), (2018).
  4. Muthu, S., et al. Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies. Nat Rev Rheumatol. 19 (7), 403-416 (2023).
  5. Lavrentieva, A., Hatlapatka, T., Neumann, A., Weyand, B., Kasper, C. Potential for osteogenic and chondrogenic differentiation of MSC. Adv Biochem Eng Biotechnol. 129, 73-88 (2013).
  6. Fernandez-Moure, J. S., et al. Enhanced osteogenic potential of mesenchymal stem cells from cortical bone: a comparative analysis. Stem Cell Res Ther. 6, 203(2015).
  7. Goldberg, A., Mitchell, K., Soans, J., Kim, L., Zaidi, R. The use of mesenchymal stem cells for cartilage repair and regeneration: a systematic review. J Orthop Surg Res. 12, 39(2017).
  8. Zha, K., et al. Heterogeneity of mesenchymal stem cells in cartilage regeneration: From characterization to application. NPJ Regen Med. 6 (1), 1-15 (2021).
  9. Hayes, A. J., Tudor, D., Nowell, M. A., Caterson, B., Hughes, C. E. Chondroitin Sulfate sulfation motifs as putative biomarkers for isolation of articular cartilage progenitor cells. J Histochem Cytochem. 56 (2), 125-138 (2008).
  10. Dowthwaite, G. P., et al. The surface of articular cartilage contains a progenitor cell population. J Cell Sci. 117 (Pt 6), 889-897 (2004).
  11. Williams, R., et al. Identification and clonal characterization of a progenitor cell sub-population in normal human articular cartilage. PloS One. 5 (10), e13246(2010).
  12. Vinod, E., Parameswaran, R., Ramasamy, B., Kachroo, U. Pondering the potential of hyaline cartilage-derived chondroprogenitors for tissue regeneration: A systematic review. Cartilage. , (2020).
  13. Khan, I. M., Bishop, J. C., Gilbert, S., Archer, C. W. Clonal chondroprogenitors maintain telomerase activity and Sox9 expression during extended monolayer culture and retain chondrogenic potential. Osteoarthritis Cartilage. 17 (4), 518-528 (2009).
  14. Fellows, C. R., et al. Characterization of a divergent progenitor cell sub-populations in human osteoarthritic cartilage: the role of telomere erosion and replicative senescence. Sci Rep. 7, 41421(2017).
  15. Vinod, E., Kachroo, U., Amirtham, S. M., Ramasamy, B., Sathishkumar, S. Comparative analysis of fresh chondrocytes, cultured chondrocytes and chondroprogenitors derived from human articular cartilage. Acta Histochem. 122 (1), 151462(2019).
  16. Korpershoek, J. V., et al. Selection of highly proliferative and multipotent meniscus progenitors through differential adhesion to Fibronectin: A novel approach in meniscus tissue engineering. Int J Mol Sci. 22 (16), 8614(2021).
  17. Wang, J., Roberts, S., Li, W., Wright, K. Phenotypic characterization of regional human meniscus progenitor cells. Front Bioeng Biotechnol. 10, 1003966(2022).
  18. Koelling, S., et al. Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis. Cell Stem Cell. 4 (4), 324-335 (2009).
  19. Seol, D., et al. Chondrogenic progenitor cells respond to cartilage injury. Arthritis Rheum. 64 (11), 3626-3637 (2012).
  20. Xue, K., et al. Isolation and identification of stem cells in different subtypes of cartilage tissue. Expert Opin Biol Ther. 15 (5), 623-632 (2015).
  21. McCarthy, H. E., Bara, J. J., Brakspear, K., Singhrao, S. K., Archer, C. W. The comparison of equine articular cartilage progenitor cells and bone marrow-derived stromal cells as potential cell sources for cartilage repair in the horse. Vet J. 192 (3), 345-351 (2012).
  22. Elsaesser, A. F., et al. Characterization of a migrative subpopulation of adult human nasoseptal chondrocytes with progenitor cell features and their potential for in vivo cartilage regeneration strategies. Cell & Biosci. 6, 11(2016).
  23. Batschkus, S., et al. Mapping the secretome of human chondrogenic progenitor cells with mass spectrometry. Ann Anat. 212, 4-10 (2017).
  24. Vinod, E., et al. Migratory chondroprogenitors retain superior intrinsic chondrogenic potential for regenerative cartilage repair as compared to human fibronectin-derived chondroprogenitors. Sci Rep. 11, 23685(2021).
  25. Vinod, E., et al. Intraarticular injection of allogenic chondroprogenitors for treatment of osteoarthritis in rabbit knee model. J Clin Orthop Trauma. 10 (1), 16-23 (2018).
  26. Xue, K., et al. Cartilage progenitor cells combined with PHBV in cartilage tissue engineering. J Trans Med. 17 (1), 104(2019).
  27. Carluccio, S., et al. Progenitor cells activated by platelet lysate in human articular cartilage as a tool for future cartilage engineering and reparative strategies. Cells. 9 (4), E1052(2020).
  28. Wang, R., et al. Intra-articular delivery of extracellular vesicles secreted by chondrogenic progenitor cells from MRL/MpJ superhealer mice enhances articular cartilage repair in a mouse injury model. Stem Cell Res Ther. 11 (1), 93(2020).
  29. Wang, H. C., Lin, T. H., Hsu, C. C., Yeh, M. L. Restoring osteochondral defects through the differentiation potential of cartilage stem/progenitor cells cultivated on porous scaffolds. Cells. 10 (12), 3536(2021).
  30. Kellgren, J. H., Lawrence, J. S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 16 (4), 494-502 (1957).
  31. Vinod, E., Kachroo, U., Rebekah, G., Yadav, B. K., Ramasamy, B. Characterization of human articular chondrocytes and chondroprogenitors derived from non-diseased and osteoarthritic knee joints to assess superiority for cell-based therapy. Acta Histochem. 122 (6), 151588(2020).
  32. Nelson, L., McCarthy, H. E., Fairclough, J., Williams, R., Archer, C. W. Evidence of a viable pool of stem cells within human osteoarthritic cartilage. Cartilage. 5 (4), 203-214 (2014).
  33. Vinod, E., et al. Comparison of methods for the isolation and culture of Migratory chondroprogenitors from Human articular cartilage. Connect Tissue Res. 64 (4), 389-399 (2023).
  34. Dominici, M., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 8 (4), 315-317 (2006).
  35. Vinod, E., Boopalan, P. R. J. V. C., Sathishkumar, S. Reserve or resident progenitors in cartilage? Comparative analysis of chondrocytes versus chondroprogenitors and their role in cartilage repair. Cartilage. , (2017).
  36. Dicks, A., et al. Prospective isolation of chondroprogenitors from human iPSCs based on cell surface markers identified using a CRISPR-Cas9-generated reporter. Stem Cell Res Ther. 11 (1), 66(2020).
  37. Vinod, E., et al. Prospective isolation and characterization of chondroprogenitors from human chondrocytes based on CD166/CD34/CD146 surface markers. Cartilage. , (2021).
  38. Vinod, E., et al. Migratory chondroprogenitors retain superior intrinsic chondrogenic potential for regenerative cartilage repair as compared to human Fibronectin-derived chondroprogenitors. Sci Rep. 11 (1), 23685(2021).
  39. Vinod, E., et al. Human fetal cartilage-derived chondrocytes and chondroprogenitors display a greater commitment to chondrogenesis than adult cartilage resident cells. PloS One. 18 (4), e0285106(2023).
  40. Joos, H., Wildner, A., Hogrefe, C., Reichel, H., Brenner, R. E. Interleukin-1 beta and tumor necrosis factor-alpha inhibit migration activity of chondrogenic progenitor cells from non-fibrillated osteoarthritic cartilage. Arthritis Res Ther. 15 (5), R119(2013).
  41. Vinod, E., Parameswaran, R., Amirtham, S. M., Rebekah, G., Kachroo, U. Comparative analysis of human bone marrow mesenchymal stem cells, articular cartilage derived chondroprogenitors and chondrocytes to determine cell superiority for cartilage regeneration. Acta Histochem. 123 (4), 151713(2021).
  42. Vinod, E., Padmaja, K., Ramasamy, B., Sathishkumar, S. Systematic review of articular cartilage derived chondroprogenitors for cartilage repair in animal models. J Orthopaed. 35, 43-53 (2022).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Chondrocyte IsolationChondroprogenitor CellsCartilage ExplantEnzymatic DigestionArticular CartilageCell CultureMesenchymal PropertiesTrypsin EDTA
Isolation of Chondrocytes and Chondroprogenitors Using Fibronectin Adhesion and Migratory Assay
Contact Us
Recommend to Library

Privacy

Terms of Use

Policies

Copyright © 2026 MyJoVE Corporation. All rights reserved.